The archived three-part webinar series provides timely information about the implementation of recently approved lenacapavir as pre-exposure prophylaxis (PrEP) to reduce the risk of acquiring HIV-1. The series covers how lenacapavir as PrEP is implemented in practice at the clinical, patient, and organizational levels. Faculty throughout the series discuss how different provider types—clinicians, patient navigators, and pharmacists—within various settings can implement this first-of-its-kind biomedical intervention.


Live webinars in this series are:

  • Lenacapavir in Clinical Practice – A Primer for Clinicians

  • Transforming PrEP Navigation: Empowering Patient Choices with Lenacapavir

  • Operationalizing Lenacapavir for PrEP in Your Health System: From Business Planning and Reimbursement to Pharmacy Readiness


Note that continuing education credits are not available for this series. Gilead provided funding to support this series. Gilead had no input into the content of the materials used at this event.



Lenacapavir in Clinical Practice – A Primer for Clinicians


In the first webinar of the series, faculty– including principal investigators from the PURPOSE trials– review clinical data and delve into opportunities and challenges for the real-world implementation of lenacapavir as PrEP. This webinar covers medication administration, managing side effects, potential drug interactions, and transitioning patients on or off lenacapavir as PrEP.


Learning Objectives:

  • Summarize the key clinical trial data that supported FDA approval of lenacapavir for HIV prevention.

  • Identify appropriate patient populations for lenacapavir as PrEP.

  • Explain the administration process, dosing schedule, and monitoring requirements for lenacapavir as PrEP.

  • Discuss practical implementation strategies, including counseling points, reimbursement, and barriers to uptake of lenacapavir PrEP.

  • Please note that continuing education credits are not available for this webinar.


Faculty:

  • Colleen Kelley, MD, MPH, Emory University

  • Onyema Ogbuagu, MBBCh, FACP, FIDSA, Yale School of Medicine

  • Hyman Scott, MD, MPH, Bridge HIV in the San Francisco Department of Public Health


Transforming PrEP Navigation and Empowering Patients through Long-acting Injectable PrEP


In the second of three webinars, faculty from organizations at different stages of implementing lenacapavir as PrEP discuss strategies to support patients in making informed decisions on the best PrEP option for them. This webinar covers patient navigation touchpoints along the PrEP continuum for injectable lenacapavir, patient education strategies, expanding the capacity of PrEP navigation staff to implement injectable PrEP, and future opportunities for expanded implementation in mobile health settings. The webinar features expert-led presentations, an engaging panel discussion, and a live Q&A to support understanding and real-world use.


Learning Objectives:

  • Describe the key features of lenacapavir as a new long-acting PrEP option.

  • Understand the roles patient navigators play in supporting successful implementation of lenacapavir as PrEP.

  • Apply lessons learned from early implementers of lenacapavir as PrEP to strengthen workflows and team coordination.


Faculty:

  • Juan Carlos Loubriel - Whitman-Walker Health, Washington, DC

  • Megan Dieterich, PA-C - Whitman-Walker Health

  • Brendan Bowns, MPH, HIVPNC - Corktown Health, Detroit, MI

  • Towanna Enoch, APRN, ANP-C - PALSS, Columbia, SC

  • Scarlet Price, CMA - PALSS


Operationalizing Lenacapavir for PrEP in Your Health System: From Business Planning and Reimbursement to Pharmacy Readiness



Lenacapavir as PrEP is a transformative advancement in HIV prevention that requires organizations to adapt existing workflow, logistics, and reimbursement strategies to fully implement this new long-acting medication. In this archived webinar, you will gain actionable insights into how to prepare your organization for lenacapavir implementation, ensure sustainability in delivery, and empower your providers to stay at the forefront of HIV prevention.

 

Expert faculty will guide you through the essential considerations for integrating lenacapavir, including:

  • National and state policy considerations that impact lenacapavir as PrEP feasibility and implementation; 

  • Reimbursement strategies, such as buy-and-bill feasibility, 340B considerations, and insurance coverage;

  • Leadership buy-in and business planning; and, 

  • Adapting workflow, staffing, EHR programming, and day-to-day operational logistics for lenacapavir as PrEP.


Educational Objectives:

  • Summarize the current policy landscape related to the implementation of lenacapavir as HIV PrEP.

  • Discuss major policy areas that are currently evolving that will impact access and administration of lenacapavir as HIV PrEP.

  • Identify potential policy trends and challenges that may impact future deployment or regulation of lenacapavir.


Faculty:

  • E. Michael Murphy, PharmD, MBA - The Ohio State University College of Pharmacy

  • Daniela E. DiMarco, MD, MPH - University of Rochester Medicine Infectious Disease Clinic

  • Erick Suarez, APRN, FNP-BC, AAHIV-S - Pineapple Healthcare